Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
852A · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| 852A | DRUG | - |
Inclusion Criteria: * Advanced melanoma not responding to 1st line chemotherapy * Histological evidence of melanoma * Measurable disease according to RECIST criteria * ECOG performance status less than or equal to 2 * Life expectancy 6 months or more * Normal organ and bone marrow function as defin...
Top 20 of 51 competitors
852A is an investigational small molecule being studied for the treatment of melanoma, including inoperable advanced melanoma skin lesions and unresectable metastatic cutaneous melanoma. It is an immune response modifier being evaluated in clinical trials for these conditions.
852A is an immune response modifier, a small molecule that modulates the immune system to fight cancer. Its specific molecular target is not disclosed in the available clinical trial information, but it is being studied for its safety and efficacy in treating melanoma skin lesions.
852A is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the drug's safety and efficacy in patients with melanoma.
852A is in Phase 2 clinical development for the treatment of melanoma. It has completed a Phase 1 trial and a Phase 2 trial, both of which are finished. The drug is investigational and has not been approved by regulatory authorities.
852A has been studied in two completed clinical trials. NCT00091689 was a Phase 1 trial in the United States evaluating safety and efficacy in inoperable advanced melanoma skin lesions. NCT00189332 was a Phase 2 trial in France, Germany, and Switzerland for unresectable metastatic cutaneous melanoma, enrolling 28 participants.
852A is not known by any alternative names in the available clinical trial information. It is referred to solely as 852A in the studies registered under NCT00091689 and NCT00189332, which are the only trials associated with this investigational drug.